Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis.

Woo J, Vierboom MP, Kwon H, Chao D, Ye S, Li J, Lin K, Tang I, Belmar NA, Hartman T, Breedveld E, Vexler V, 't Hart BA, Law DA, Starling GC.

Arthritis Res Ther. 2013;15(6):R207.

2.

The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.

Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P, Boumpas DT.

Arthritis Rheum. 2010 Jul;62(7):1870-80. doi: 10.1002/art.27500.

3.

Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium.

Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C.

PLoS Med. 2009 Jan 13;6(1):e1. doi: 10.1371/journal.pmed.0060001.

4.

Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis.

Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N.

Arthritis Rheum. 2005 Oct;52(10):3004-14.

5.

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.

Koenders MI, Marijnissen RJ, Joosten LA, Abdollahi-Roodsaz S, Di Padova FE, van de Loo FA, Dulos J, van den Berg WB, Boots AM.

Arthritis Rheum. 2012 Jun;64(6):1762-70. doi: 10.1002/art.34352. Epub 2011 Dec 27.

6.

Cyr61 is involved in neutrophil infiltration in joints by inducing IL-8 production by fibroblast-like synoviocytes in rheumatoid arthritis.

Zhu X, Xiao L, Huo R, Zhang J, Lin J, Xie J, Sun S, He Y, Sun Y, Zhou Z, Shen B, Li N.

Arthritis Res Ther. 2013;15(6):R187.

7.

Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.

Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.

Xenotransplantation. 2001 Aug;8(3):157-71.

PMID:
11472623
8.
9.

Inhibition of synovitis and joint destruction by a new single domain antibody specific for cyclophilin A in two different mouse models of rheumatoid arthritis.

Wang L, Jia J, Wang C, Ma X, Liao C, Fu Z, Wang B, Yang X, Zhu P, Li Y, Chen Z.

Arthritis Res Ther. 2013;15(6):R208.

10.

Development of a new humanized mouse model to study acute inflammatory arthritis.

Misharin AV, Haines GK 3rd, Rose S, Gierut AK, Hotchkiss RS, Perlman H.

J Transl Med. 2012 Sep 13;10:190. doi: 10.1186/1479-5876-10-190.

11.

Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera.

Matsuno H, Yudoh K, Nakazawa F, Sawai T, Uzuki M, Nishioka K, Yonehara S, Nakayama J, Ohtsuki M, Kimura T.

J Rheumatol. 2002 Aug;29(8):1609-14.

PMID:
12180717
12.

IL-17 increases cadherin-11 expression in a model of autoimmune experimental arthritis and in rheumatoid arthritis.

Park YE, Woo YJ, Park SH, Moon YM, Oh HJ, Kim JI, Jin HS, Baek SH, Kim GT, Lee JH, Cho ML, Kim SI.

Immunol Lett. 2011 Oct 30;140(1-2):97-103. doi: 10.1016/j.imlet.2011.07.003. Epub 2011 Jul 20.

PMID:
21798287
13.

Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice.

Ishizuka Y, Moriwaki S, Kawahara-Hanaoka M, Uemura Y, Serizawa I, Miyauchi M, Shibata S, Kanaya T, Takata T, Taniguchi N, Niida S.

J Bone Miner Res. 2007 Dec;22(12):1933-42.

14.

Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.

Kwok SK, Cho ML, Park MK, Oh HJ, Park JS, Her YM, Lee SY, Youn J, Ju JH, Park KS, Kim SI, Kim HY, Park SH.

Arthritis Rheum. 2012 Mar;64(3):740-51. doi: 10.1002/art.33390.

15.

Local production of complement proteins in rheumatoid arthritis synovium.

Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, Kullmann F, Mountz JD, Schölmerich J, Gay S, Müller-Ladner U.

Arthritis Rheum. 2002 Apr;46(4):934-45.

PMID:
11953970
16.

Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model.

Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N, Yoshizaki K.

Arthritis Rheum. 1998 Nov;41(11):2014-21.

PMID:
9811057
17.

Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients.

Reparon-Schuijt CC, van Esch WJ, van Kooten C, Levarht EW, Breedveld FC, Verweij CL.

Arthritis Rheum. 1998 Dec;41(12):2211-20.

PMID:
9870878
18.

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.

Arthritis Rheum. 2007 Dec;56(12):3909-18.

19.

Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures.

Ultaigh SN, Saber TP, McCormick J, Connolly M, Dellacasagrande J, Keogh B, McCormack W, Reilly M, O'Neill LA, McGuirk P, Fearon U, Veale DJ.

Arthritis Res Ther. 2011 Feb 23;13(1):R33. doi: 10.1186/ar3261.

20.
Items per page

Supplemental Content

Write to the Help Desk